Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

.

Source: Amyloid: The Journal of Protein Folding Disorders - March 4, 2020 Category: Biochemistry Authors: Laura Obici John L. Berk Alejandra Gonz ález-Duarte Teresa Coelho Julian Gillmore Hartmut H.-J. Schmidt Matthias Schilling Taro Yamashita C éline Labeyrie Thomas H. Brannagan Senda Ajroud-Driss Peter Gorevic Arnt V. Kristen Jaclyn Franklin Jihong Chen M Source Type: research